<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="other" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <front>
    <journal-meta>
      <journal-id journal-id-type="pmc">JRMS</journal-id>
      <journal-id journal-id-type="pubmed">J Res Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">Journal of Research in Medical Sciences</journal-id>
      <journal-title>Journal of Research in Medical Sciences</journal-title>
      <issn pub-type="ppub">1735-1995</issn>
	<issn pub-type="epub">1735-7136</issn>
      <publisher>
        <publisher-name>Medknow Publications Pvt Ltd</publisher-name>
	<publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JRMS-18-848</article-id>
      <article-id pub-id-type="pmid">24497854</article-id>
      <article-categories>
	<subj-group subj-group-type="headings">
		<subject>Original Article</subject>
	</subj-group>
      </article-categories>
      <title-group>
        <article-title>Comparison of five staging systems of lymph node metastasis in the gastric carcinoma</article-title>
      </title-group>
	<contrib-group>
<contrib contrib-type="author">
<name><surname>Chehrei</surname>
<given-names>Ali</given-names></name>
<xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author">
<name><surname>Amoueian</surname>
<given-names>Sakineh</given-names></name>
<xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author">
<name><surname>Ansari</surname>
<given-names>Jamshid</given-names></name>
<xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author">
<name><surname>Montazer</surname>
<given-names>Mehdi</given-names></name>
<xref ref-type="aff" rid="aff4"/></contrib>
<contrib contrib-type="author">
<name><surname>Sanei</surname>
<given-names>Mohammad H</given-names></name>
<xref ref-type="aff" rid="aff5"/><xref ref-type="corresp" rid="cor1"/></contrib>
</contrib-group>
<aff id="aff1">Department of Pathology, Thyroid Research Center, Arak University of Medical Science, Arak, Iran</aff><aff id="aff2">Department of Pathology, Mashhad University of Medical Science, Mashhad, Iran</aff><aff id="aff3">Department of Oncology, Arak University of Medical Science, Arak, Iran</aff><aff id="aff4">Department of Pathology, Mashhad University of Medical Science, Mashhad, Iran</aff><aff id="aff5">Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran</aff>

      <author-notes>
	<corresp id="cor1"><bold>Address for correspondence:</bold>Mohammad Sanei, Isfahan University of Medical Sciences, Isfahan, Iran <email xlink:href="sanei@med.mui.ac.ir">sanei@med.mui.ac.ir</email></corresp>

      </author-notes>
      <pub-date pub-type="ppub">
        <season>October</season>
        <year>2013</year>
      </pub-date>
      <volume>18</volume>
      <issue>10</issue>
      <fpage>848</fpage>
      <lpage>854</lpage>   
      
<history>
<date date-type="received"><day>25</day><month>11</month><year>2012</year></date>

<date date-type="rev-recd"><day>17</day><month>1</month><year>2013</year></date>
</history>

      <permissions>
        <copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
      </permissions>
      <abstract><sec id="st1"><title>Background:</title><p> The presence of metastatic lymph nodes is the most important prognostic factor for gastric carcinoma; however, the optimal system for the accurate staging of lymph node metastasis for patients with gastric cancer remains controversial. This study was designed to compare five systems in relation to the N classification of gastric carcinoma. <sec id="st1"><title>Materials and Methods:</title><p> This multicentric historical cohort study was conducted on 148 patients with M0 gastric adenocarcinoma who underwent gastrectomy in, five referral hospitals in Iran. Lymph nodes were sectioned, stained with hematoxyl in and eosin. The lymph node status was classified according to the five systems which are: The number of involved lymph nodes (TNM staging), metastatic lymph node ratio (N ratio), and the largest involved lymph node size, largest metastatic nest size and largest metastatic nest to lymph node size ratio. <sec id="st1"><title>Results:</title><p> Patients were classified into significant prognostic groups by the five N classification method including the TNM method, N ratio (0, &#8804;0.15, 0.15-0.4, &gt;0.4), largest involved lymph node size (0, &#8804;5, 5-11, &gt;11 mm), Largest metastatic nest size (&#8804;1, 1-7.5, &gt;7.5 mm) and largest metastatic nest to lymph node size ratio (&#8804;0.3, 0.3-0.9, &gt;0.9). All of the above systems remained as independently significant prognostic factors in terms of overall and disease free survival time. <sec id="st1"><title>Conclusion:</title><p> Among the N staging systems we recommend the metastatic lymph node ratio and largest metastatic nest to lymph node size systems, since they are reproducible, simple, have good survival applicability, have prognostic value and include less stage migration especially in patients whom fewer than 15 lymph nodes are dissected.</p>
</sec>
<sec id="st2"><title>Materials and Methods:</title><p> This multicentric historical cohort study was conducted on 148 patients with M0 gastric adenocarcinoma who underwent gastrectomy in, five referral hospitals in Iran. Lymph nodes were sectioned, stained with hematoxyl in and eosin. The lymph node status was classified according to the five systems which are: The number of involved lymph nodes (TNM staging), metastatic lymph node ratio (N ratio), and the largest involved lymph node size, largest metastatic nest size and largest metastatic nest to lymph node size ratio. <sec id="st2"><title>Results:</title><p> Patients were classified into significant prognostic groups by the five N classification method including the TNM method, N ratio (0, &#8804;0.15, 0.15-0.4, &gt;0.4), largest involved lymph node size (0, &#8804;5, 5-11, &gt;11 mm), Largest metastatic nest size (&#8804;1, 1-7.5, &gt;7.5 mm) and largest metastatic nest to lymph node size ratio (&#8804;0.3, 0.3-0.9, &gt;0.9). All of the above systems remained as independently significant prognostic factors in terms of overall and disease free survival time. <sec id="st2"><title>Conclusion:</title><p> Among the N staging systems we recommend the metastatic lymph node ratio and largest metastatic nest to lymph node size systems, since they are reproducible, simple, have good survival applicability, have prognostic value and include less stage migration especially in patients whom fewer than 15 lymph nodes are dissected.</p>
</sec>
<sec id="st3"><title>Results:</title><p> Patients were classified into significant prognostic groups by the five N classification method including the TNM method, N ratio (0, &#8804;0.15, 0.15-0.4, &gt;0.4), largest involved lymph node size (0, &#8804;5, 5-11, &gt;11 mm), Largest metastatic nest size (&#8804;1, 1-7.5, &gt;7.5 mm) and largest metastatic nest to lymph node size ratio (&#8804;0.3, 0.3-0.9, &gt;0.9). All of the above systems remained as independently significant prognostic factors in terms of overall and disease free survival time. <sec id="st3"><title>Conclusion:</title><p> Among the N staging systems we recommend the metastatic lymph node ratio and largest metastatic nest to lymph node size systems, since they are reproducible, simple, have good survival applicability, have prognostic value and include less stage migration especially in patients whom fewer than 15 lymph nodes are dissected.</p>
</sec>
<sec id="st4"><title>Conclusion:</title><p> Among the N staging systems we recommend the metastatic lymph node ratio and largest metastatic nest to lymph node size systems, since they are reproducible, simple, have good survival applicability, have prognostic value and include less stage migration especially in patients whom fewer than 15 lymph nodes are dissected.</p>
</sec>
</abstract>
      <kwd-group><kwd>Gastric carcinoma</kwd>
<kwd>lymph node metastasis</kwd>
<kwd>metastatic nest</kwd>
<kwd>staging</kwd>
<kwd>TNM system</kwd>
</kwd-group>	
      
    </article-meta>
  </front>
  <body>
	<sec><title/>
</sec><sec><title>Introduction</title><p>Gastric cancer is a universally common cancer <sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and the second most common cause of cancer related death. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Lymph node metastasis is reported to be one of the most important prognostic factors for gastric carcinoma. <sup><xref ref-type="bibr" rid="ref3">3</xref></sup>,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup>,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> </p>

<p>The Tumor-Node-Metastasis staging method (TNM) staging system is a widely accepted method for the determination of prognosis and therapeutic plan. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup> This system has been affected by increase of lymph node dissection and the pathologist&#x2032;s accuracy in finding the number of lymph nodes in the gastrectomy specimen. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Furthermore, extended lymphadenectomy can cause stage migration due to increase in the number of metastatic lymph nodes. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Many authors suggest that the lymph node staging system based on TNM classification will not be affected by the extent of lymph node dissection. <sup><xref ref-type="bibr" rid="ref1">1</xref></sup>,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Some authors have shown that staging based on the metastatic lymph node ratio (N ratio), which is calculated by dividing the number of metastatic lymph nodes by the total number of nodes is an independent and easy-to-assess prognostic factor for patients with gastric cancer. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup>,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> </p>

<p>Recent findings about esophageal and colon cancer patients suggest that largest involved lymph node size is a more important prognostic factor in these patients than the number of lymph nodes involved; <sup><xref ref-type="bibr" rid="ref20">20</xref></sup>,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup>,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup>,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> but in the case of gastric carcinoma there is a little evidence to show that lymph node size and metastatic nest size are prognostic factors. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> </p>

<p>In this study, we compare five methods of N classification of gastric carcinoma including TNM, N ratio, largest involved lymph node size, largest metastatic nest size, and the largest metastatic nest to lymph node size ratio for the prediction of survival and disease free survival time (DFS).</p>


</sec><sec sec-type='materials|methods'><title>Materials and Methods</title><p>This multicentric historical cohort study was conducted on 148 patients with M0 gastric adenocarcinoma who underwent surgery during 2002-2010: In Valiasr, Emam Khomeini, Ghods (Arak, Iran), Alzahra (Isfahan, Iran) and Emam-Reza Hospitals (Mashhad, Iran). All patients were included if they underwent curative total or partial gastrectomy for M0 primary gastric adenocarcinoma. They were excluded if they had undergone surgery for lymphoma, gastrointestinal stromal tumor, peptic ulcer, and other diseases. Patients without lymph node metastasis and patients who had distant or peritoneal metastasis were also excluded. In all cases, diagnosis had been confirmed at least 1 year before the beginning of our study.</p>

<p>All dissected lymph nodes cut along their longest axis and fixed in formalin, embedded in paraffin, three micron section were prepared and the slides were stained with hematoxyl in and eosin.</p>

<p>All the slides were reviewed by two pathologists and a consensus meeting was held in case of discrepancy. These pathologists had no information regarding the patients&#x2032; prognosis (including survival or recurrence).</p>

<p>Important microscopic features were recorded, these include: Type of Adenocarcinoma (signet, intestinal), grade (poorly, moderately, and well-differentiated), stage, number of dissected and involved lymph nodes, largest size of involved the lymph nodes, largest metastatic nest diameter, and largest metastatic nest to lymph node diameter ratio.</p>

<p>The five systems were explained as bellow;</p>

<p>First: the node ratio (N ratio); the ratio of the number of involved lymph node to the total number of harvesting lymph nodes.</p>

<p>Second: the largest involve lymph node size; among involve lymph node the size of largest one was selected.</p>

<p>Third: the largest metastatic nest size; involve lymph nodes nest were mark under 40 magnifications. Then by microscopic ruler the size was measured and the largest one was selected. In case of multiple nests in one lymph node the sum of diameter of all were considered.</p>

<p>Forth: the largest metastatic nest to lymph node size ratio; for every involved lymph node the ratio of metastatic nest size to diameter of lymph node was calculated then among them the biggest ratio was selected.</p>

<p>Fifth: the well-known TNM system.</p>

<p><xref ref-type="table" rid="T1">Table 1</xref> shows each classification method.{Table 1}</p>

<p>Then, the survival rate and recurrence rate and disease free survival period of patients were determined. These patients were visited by an oncologist or surgeon and survival and recurrence rates were determined.</p>

<p>Then, we determined the optimal cut off points of the N ratio, the largest involved lymph node size, the largest metastatic nest size and the largest metastatic nest to lymph node size ratio, which can predict prognosis (including survival time and DFS).</p>

<p>Finally, survival and DFS in the subgroups of each method were compared.</p>

<p>All data were analyzed by spss software (spss Inc., Chicago IL, VSA, version 16).</p>

<p>Simple descriptive techniques were used to describe the variables among the participants. The K-S and levene&#x2032;s test were applied to verify normal distribution and equality of variances. According to the results of the tests, mentioned above, we used the student t-test or Mann-withney U test for the comparison of the quantitative data in grouping variables. The Chi square test was used to find the relationship between the qualitative data. Receiver operating characteristic curves and sensitivity analysis were used to determine the optimal cut-off value of the N ratio, largest involved lymph node size, largest metastatic nest size, largest Metastatic to lymph node size ratio. Actuarial and Kaplan-Meier methods were used to estimate the survival function. Survival functions were compared by using the log-rank test between the subgroups.</p>

<p>All procedures were performed according to the principle of the Ethical Standards Committee of Arak (Iran) University of Medical Sciences.</p>


</sec><sec><title>Result</title><p>A total of 148 cases of gastric cancer in the time interval ranging from 2002 to 2010 reported in five hospitals in Iran were evaluated. The patients included 106 men (71.6&#x0025;) and 42 women (28.4&#x0025;). The mean age was 63.09 years (range = 27-85). Lymph node metastasis was observed in 114 cases. (77.02&#x0025;)</p>

<p>The number of dissected lymph nodes per patient varied widely (1-48), with mean of 9.26. The mean primary tumor size was 5.7 cm (5.26-6.15). The 5-year overall survival rate was 16&#x0025; <xref ref-type="fig" rid="F1">Figure 1</xref> and the median of overall survival time were 16 months. (10.72-21.27). The median of overall DFS was 12 months (8.46-15.53). 102 (68.91&#x0025;) patients were died by the end of follow-up. The results of the comparative analysis of demographics clinical and pathological features are shown in <xref ref-type="table" rid="T2">Table 2</xref>.<fig id="F1"><label>Figure 1</label><caption><p>Survival function of all cases of gastric carcinoma</p>
</caption><alt-text>Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f5.tif"/></fig>{Table 2}</p>

<p>Median survival times were not significantly different between the subgroups of the clinicopathological parameters including sex, age, and site of tumor, type of gastrectomy, histological type, and grade of adenocarcinoma.</p>

<p>The numbers of patients in each nodal group is shown in <xref ref-type="table" rid="T3">Table 3</xref>. The comparative analysis of survival and DFS in each nodal group according to the five nodal classification systems is presented in <xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Figure 2</xref>, <xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="fig" rid="F6">Figure 6</xref>.<fig id="F2"><label>Figure 2</label><caption><p>Survival functions of gastric carcinoma according to II ratio classification</p>
</caption><alt-text>Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f6.tif"/></fig><fig id="F3"><label>Figure 3</label><caption><p>Survival functions of gastric carcinoma according to largest lymph node size classification</p>
</caption><alt-text>Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f7.tif"/></fig><fig id="F4"><label>Figure 4</label><caption><p>Survival functions of gastric carcinoma according to the largest metastatic nest size</p>
</caption><alt-text>Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f8.tif"/></fig><fig id="F5"><label>Figure 5</label><caption><p>Survival functions of gastric carcinoma according to largest metastatic nest to lymph node size ratio</p>
</caption><alt-text>Figure 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f9.tif"/></fig><fig id="F6"><label>Figure 6</label><caption><p>Survival functions of gastric carcinoma according to TNM classification</p>
</caption><alt-text>Figure 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_10_848_124885_f10.tif"/></fig>{Table 3}{Table 4}</p>


</sec><sec><title>Discussion</title><p>Lymph node metastasis is one of the most important prognostic factors of gastric cancer. <sup><xref ref-type="bibr" rid="ref25">25</xref></sup>,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup>,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup>,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> At present, the classification of lymph node involvement in gastric cancer is still under extensive evaluation; there are some objectives for tumor staging: Assisting in the definition of clinical treatment, simplicity, surgical applicability, and providing some prognostic information for patients. To accomplish these objectives, every lymph node metastasis classification system should be simple, accurate, reproducible and prognostic relevance without stage migration. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Reproducibility is crucial for post-treatment pathological classification, inter, and intra observer variability has to be low. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup> According to each lymph node metastasis classification, the prognosis can be estimated and determine the therapeutic strategy planning. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> </p>

<p>It has been suggested that the number of metastasis lymph nodes (TNM staging) is a widely accepted, convenience, reproducible method with good assessing potential for the prognosis of gastric cancer. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup>,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup>,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> This staging system is influenced by the number of the resected and examined lymph node. Although N classification is recommended the 15 or more lymph nodes should be examined for accurate staging of gastric carcinoma, <sup><xref ref-type="bibr" rid="ref32">32</xref></sup> the number of metastatic lymph nodes increases in proportion to the number of dissected nodes, suggesting that the patient classified as N1 after limited lymph node dissection may be classified as N2 or N3 after extensive lymphadenectomy. On the other hand, the N classification may be changed by adding or reducing one or more positive lymph nodes. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> This phenomenon is the so called stage migration error. Stage migration occurs in 5-15&#x0025; of gastric cancer cases, after extensive lymphadenectomy. <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> In addition, when fewer than 15 lymph nodes are detected, the probability of stage migration rises.</p>

<p>Another method for N classification in gastric cancer is N ratio, which is calculated by dividing the number of metastatic lymph nodes by the total number of nodes harvested. This factor reflects both tumor characteristics: The number of metastatic lymph nodes and the extent of lymphadenectomy. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup> This system is convenient, reproducible and has surgical applicability, high ability to predict survival and reduced stage migration. In addition, the N ratio system is applicable in patients when fewer than 15 lymph nodes are dissected. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup>,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup>,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> </p>

<p>There has been no consensus about N ratio cut-off value for the classification of the N status in gastric carcinoma and the definition of the significant prognostic cut-off point varies. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup>,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup>,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup>,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Many authors have shown a significant deterioration in prognosis when 25&#x0025; of the removed lymph nodes were positive and in some studies three (&lt;10&#x0025;, 10-25&#x0025;, &gt;25&#x0025;) or four (0, &lt;10&#x0025;, 10-25&#x0025;, &gt;25&#x0025;) subgroups of cases with different survival time were identified. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup>,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> In the present study, four subgroups of patients with remarkably different median survival time were identified: 0, &lt;15&#x0025;, 15-40&#x0025; and &gt;40&#x0025;. We also tried to analyze the median of survival time and DFS of our cases and classify them with other cut-off points including 10&#x0025; and 25&#x0025;, but in the present study cut off points of 0, 15&#x0025;, and 40&#x0025; have the best significant different median of survival time between the subgroups. Lim et al. in the same study reported a significantly difference in survival rate when more than 40&#x0025; of removed lymph nodes were invaded. <sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Persiani et al. reported three subgroups of patients with significantly different 5-year survival rates by 2 cut-off points 15 and 40&#x0025; (N1: Ratio &lt;15&#x0025;, N2: Ratio 15-40&#x0025;, N3: Ratio &gt;40&#x0025;) <sup><xref ref-type="bibr" rid="ref5">5</xref></sup> we stratified the patients into four N ratio groups with three cut-off points (0, 15, 40&#x0025;) rather than three N ratio groups with two cut-off points (15 and 40&#x0025;); based on the hypothesis that gastric cancer with no nodal involvement should not be grouped with gastric cancer with nodal involvement. The cut-off point of zero was determined in the present study. In the literature review, other authors confirm the above hypothesis. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>,<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> </p>

<p>The N ratio system for the classification of gastric cancer N staging is a simple, accurate and reproducible method, but routine hematoxylin and eosin staining may not exactly reflect the lymph node metastasis due to lymph node micro-metastasis. <sup><xref ref-type="bibr" rid="ref14">14</xref></sup> </p>

<p>Others methods examined in this study for N classification of gastric cancer depend on the size of the lymph node and metastatic nest. There are several reports that the largest involved lymph node size may be useful for N classification in esophageal and colon cancer; <sup><xref ref-type="bibr" rid="ref20">20</xref></sup>,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup>,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup>,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> however, attention to the largest involved lymph node size in N classification of gastric carcinoma has been rare.</p>

<p>Two previous study divided patients into two groups: Lymph node size &lt;2 cm, &gt; = 2 cm and found that this method was an independent prognostic factor. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> Dhar et al. in another study suggested a 7 mm or less cut-off point in the n classification of a number of patients who were then assigned to group N1, a second group that is group N2 had a8 mm or more cut-off point. <sup><xref ref-type="bibr" rid="ref24">24</xref></sup> These above methods stratified patients into three groups (N0, N1, N2) with 2 cut- off points (7, 20 mm), but we stratified patients into 4 groups (N0, N1, N2, N3) with three cut-off points (0, 5, 11 mm). Since our classification is divided into four groups, this method is comparable with other classifications. Furthermore, it seems that both the size of lymph node and the size of the metastatic nest have theoretical value in the classification of N groups. Our study showed that the largest metastatic nest size was an independent prognostic factor in terms of overall and DFS.</p>

<p>It seems, in a theoretical approach, two factors that is metastatic nest size and lymph node size are important in the N classification of gastric carcinoma according to size; We described a factor for the classification of gastric cancer N groups according to the above two factors, we named this factor the largest metastatic nest to lymph node size ratio (MLS ratio). In this study, metastatic nest to lymph node diameter ratio was calculated for each lymph node and the largest ratio selected. MLS ratio is an independent prognostic factor in terms of overall and disease free survival rate. This method for gastric cancer N classification is a simple technique and needs only a standard microscopic ruler. This method is applicable especially in patients with fewer than 15 lymph nodes removed during surgery.</p>


</sec><sec><title>Conclusion</title><p>From among the N staging system we recommend the metastatic lymph node ratio and the largest metastatic nest to lymph node size systems, since they are reproducible, simple, have good survival applicability, have prognostic value and include less stage migration specially in patients whom fewer than 15 lymph nodes are dissected.</p>
</sec>
  </body>
  <back>
	
	
	    <ref-list><ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Huang</surname>
  <given-names>CM</given-names>
</name>
<name> 
  <surname>Lin</surname>
  <given-names>JX</given-names>
</name>
<name> 
  <surname>Zheng</surname>
  <given-names>CH</given-names>
</name>
<name> 
  <surname>Li</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Xie</surname>
  <given-names>JW</given-names>
</name>
<name> 
  <surname>Lin</surname>
  <given-names>BJ</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy</article-title><source>World J Gastroenterol</source>
<year>2010</year>
<volume>16</volume>
<fpage>2055</fpage>
<lpage>60</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Parkin</surname>
  <given-names>DM</given-names>
</name>
<name> 
  <surname>Bray</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Ferlay</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Pisani</surname>
  <given-names>P</given-names>
</name>
</person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source>
<year>2005</year>
<volume>55</volume>
<fpage>74</fpage>
<lpage>108</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Ikeguchi</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Murakami</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>Kanaji</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Ohro</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Maeta</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Yamaguchi</surname>
  <given-names>K</given-names>
</name>
 <etal/>
</person-group><article-title>Lymph node metastasis of gastric cancer: Comparison of Union International Contra Cancer and Japanese systems</article-title><source>ANZ J Surg</source>
<year>2004</year>
<volume>74</volume>
<fpage>852</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Lim do</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>HS</given-names>
</name>
<name> 
  <surname>Park</surname>
  <given-names>YS</given-names>
</name>
<name> 
  <surname>Lee</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Park</surname>
  <given-names>SH</given-names>
</name>
<name> 
  <surname>Lim</surname>
  <given-names>HY</given-names>
</name>
 <etal/>
</person-group><article-title>Metastatic lymph node in gastric cancer; is it a real distant metastasis&#x003F;</article-title><source>BMC Cancer</source>
<year>2010</year>
<volume>10</volume>
<fpage>25</fpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Persiani</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Rausei</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Antonacci</surname>
  <given-names>V</given-names>
</name>
<name> 
  <surname>Biondi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Casella</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Ciccoritti</surname>
  <given-names>L</given-names>
</name>
 <etal/>
</person-group><article-title>Metastatic lymph node ratio: A new staging system for gastric cancer</article-title><source>World J Surg</source>
<year>2009</year>
<volume>33</volume>
<fpage>2106</fpage>
<lpage>11</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Aurello</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>D&#x2032;Angelo</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Rossi</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Bellagamba</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Cicchini</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Nigri</surname>
  <given-names>G</given-names>
</name>
 <etal/>
</person-group><article-title>Classification of lymph node metastases from gastric cancer: Comparison between N-site and N-number systems.Our experience and review of the literature</article-title><source>Am Surg</source>
<year>2007</year>
<volume>73</volume>
<fpage>359</fpage>
<lpage>66</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Nitti</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>Marchet</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Olivieri</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Ambrosi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Mencarelli</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Belluco</surname>
  <given-names>C</given-names>
</name>
 <etal/>
</person-group><article-title>Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: Analysis of a large European monoinstitutional experience</article-title><source>Ann Surg Oncol</source>
<year>2003</year>
<volume>10</volume>
<fpage>1077</fpage>
<lpage>85</lpage>
</nlm-citation>
</ref>
<ref id="ref8">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Zhang</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Zhu</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Ma</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Xue</surname>
  <given-names>Y</given-names>
</name>
</person-group><article-title>Comparison of four staging systems of lymph node metastasis in gastric cancer</article-title><source>World J Surg</source>
<year>2009</year>
<volume>33</volume>
<fpage>2383</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref9">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Bando</surname>
  <given-names>E</given-names>
</name>
<name> 
  <surname>Yonemura</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Taniguchi</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Fushida</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Fujimura</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Miwa</surname>
  <given-names>K</given-names>
</name>
</person-group><article-title>Outcome of ratio of lymph node metastasis in gastric carcinoma</article-title><source>Ann Surg Oncol</source>
<year>2002</year>
<volume>9</volume>
<fpage>775</fpage>
<lpage>84</lpage>
</nlm-citation>
</ref>
<ref id="ref10">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Inoue</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Nakane</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Iiyama</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Sato</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Kanbara</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Nakai</surname>
  <given-names>K</given-names>
</name>
 <etal/>
</person-group><article-title>The superiority of ratio-based lymph node staging in gastric carcinoma</article-title><source>Ann Surg Oncol</source>
<year>2002</year>
<volume>9</volume>
<fpage>27</fpage>
<lpage>34</lpage>
</nlm-citation>
</ref>
<ref id="ref11">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Park</surname>
  <given-names>JM</given-names>
</name>
<name> 
  <surname>Ryu</surname>
  <given-names>WS</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Park</surname>
  <given-names>SS</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>SJ</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>CS</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic factors for advanced gastric cancer: Stage-stratified analysis of patients who underwent curative resection</article-title><source>Cancer Res Treat</source>
<year>2006</year>
<volume>38</volume>
<fpage>13</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref12">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Karpeh</surname>
  <given-names>MS</given-names>
</name>
<name> 
  <surname>Leon</surname>
  <given-names>L</given-names>
</name>
<name> 
  <surname>Klimstra</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>Brennan</surname>
  <given-names>MF</given-names>
</name>
</person-group><article-title>Lymph node staging in gastric cancer: Is location more important than Number.An analysis of 1,038 patients&#x003F;</article-title><source>Ann Surg</source>
<year>2000</year>
<volume>232</volume>
<fpage>362</fpage>
<lpage>71</lpage>
</nlm-citation>
</ref>
<ref id="ref13">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Fukuda</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Sugiyama</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Midorikawa</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Mushiake</surname>
  <given-names>H</given-names>
</name>
</person-group><article-title>Prognostic significance of the metastatic lymph node ratio in gastric cancer patients</article-title><source>World J Surg</source>
<year>2009</year>
<volume>33</volume>
<fpage>2378</fpage>
<lpage>82</lpage>
</nlm-citation>
</ref>
<ref id="ref14">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Cheong</surname>
  <given-names>O</given-names>
</name>
<name> 
  <surname>Oh</surname>
  <given-names>ST</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>BS</given-names>
</name>
<name> 
  <surname>Yook</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Im</surname>
  <given-names>JT</given-names>
</name>
 <etal/>
</person-group><article-title>Large metastatic lymph node size, especially more than 2 cm: Independent predictor of poor prognosis in node-positive gastric carcinoma</article-title><source>World J Surg</source>
<year>2008</year>
<volume>32</volume>
<fpage>262</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="ref15">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Rodr&#237;guez Santiago</surname>
  <given-names>JM</given-names>
</name>
<name> 
  <surname>Mu&#241;oz</surname>
  <given-names>E</given-names>
</name>
<name> 
  <surname>Mart&#237;</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Quintana</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Veloso</surname>
  <given-names>E</given-names>
</name>
<name> 
  <surname>Marco</surname>
  <given-names>C</given-names>
</name>
</person-group><article-title>Metastatic lymph node ratio as a prognostic factor in gastric cancer</article-title><source>Eur J Surg Oncol</source>
<year>2005</year>
<volume>31</volume>
<fpage>59</fpage>
<lpage>66</lpage>
</nlm-citation>
</ref>
<ref id="ref16">
<label>16</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Kunisaki</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Shimada</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Nomura</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Matsuda</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Otsuka</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Ono</surname>
  <given-names>H</given-names>
</name>
 <etal/>
</person-group><article-title>Clinical impact of metastatic lymph node ratio in advanced gastric cancer</article-title><source>Anticancer Res</source>
<year>2005</year>
<volume>25</volume>
<fpage>1369</fpage>
<lpage>75</lpage>
</nlm-citation>
</ref>
<ref id="ref17">
<label>17</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Cheong</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Hyung</surname>
  <given-names>WJ</given-names>
</name>
<name> 
  <surname>Shen</surname>
  <given-names>JG</given-names>
</name>
<name> 
  <surname>Song</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Choi</surname>
  <given-names>SH</given-names>
</name>
 <etal/>
</person-group><article-title>The N ratio predicts recurrence and poor prognosis in patients with node-positive early gastric cancer</article-title><source>Ann Surg Oncol</source>
<year>2006</year>
<volume>13</volume>
<fpage>377</fpage>
<lpage>85</lpage>
</nlm-citation>
</ref>
<ref id="ref18">
<label>18</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Huang</surname>
  <given-names>CM</given-names>
</name>
<name> 
  <surname>Lin</surname>
  <given-names>BJ</given-names>
</name>
<name> 
  <surname>Lu</surname>
  <given-names>HS</given-names>
</name>
<name> 
  <surname>Zhang</surname>
  <given-names>XF</given-names>
</name>
<name> 
  <surname>Li</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Xie</surname>
  <given-names>JW</given-names>
</name>
</person-group><article-title>Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus</article-title><source>World J Gastroenterol</source>
<year>2008</year>
<volume>14</volume>
<fpage>4383</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref19">
<label>19</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Persiani</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Rausei</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Biondi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Boccia</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Cananzi</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>D&#x2032;Ugo</surname>
  <given-names>D</given-names>
</name>
</person-group><article-title>Ratio of metastatic lymph nodes: Impact on staging and survival of gastric cancer</article-title><source>Eur J Surg Oncol</source>
<year>2008</year>
<volume>34</volume>
<fpage>519</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="ref20">
<label>20</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Dhar</surname>
  <given-names>DK</given-names>
</name>
<name> 
  <surname>Yoshimura</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Kinukawa</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Maruyama</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Tachibana</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Kohno</surname>
  <given-names>H</given-names>
</name>
 <etal/>
</person-group><article-title>Metastatic lymph node size and colorectal cancer prognosis</article-title><source>J Am Coll Surg</source>
<year>2005</year>
<volume>200</volume>
<fpage>20</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref21">
<label>21</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Komori</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Doki</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Kabuto</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Ishikawa</surname>
  <given-names>O</given-names>
</name>
<name> 
  <surname>Hiratsuka</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Sasaki</surname>
  <given-names>Y</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic significance of the size of cancer nests in metastatic lymph nodes in human esophageal cancers</article-title><source>J Surg Oncol</source>
<year>2003</year>
<volume>82</volume>
<fpage>19</fpage>
<lpage>27</lpage>
</nlm-citation>
</ref>
<ref id="ref22">
<label>22</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Dhar</surname>
  <given-names>DK</given-names>
</name>
<name> 
  <surname>Tachibana</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Kinukawa</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Riruke</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Kohno</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Little</surname>
  <given-names>AG</given-names>
</name>
 <etal/>
</person-group><article-title>The prognostic significance of lymph node size in patients with squamous esophageal cancer</article-title><source>Ann Surg Oncol</source>
<year>2002</year>
<volume>9</volume>
<fpage>1010</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="ref23">
<label>23</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Mokarian</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Sanei</surname>
  <given-names>MH</given-names>
</name>
<name> 
  <surname>Chehrei</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Nurozi</surname>
  <given-names>V</given-names>
</name>
<name> 
  <surname>Nurozi</surname>
  <given-names>AA</given-names>
</name>
</person-group><article-title>The relationship between involved lymph nodes, metastatic nest diameters and prognosis in colorectal cancer</article-title><source>J Gastrointestin Liver Dis</source>
<year>2008</year>
<volume>17</volume>
<fpage>305</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref24">
<label>24</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Dhar</surname>
  <given-names>DK</given-names>
</name>
<name> 
  <surname>Kubota</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Kinukawa</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Maruyama</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Kyriazanos</surname>
  <given-names>ID</given-names>
</name>
<name> 
  <surname>Ohno</surname>
  <given-names>S</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic significance of metastatic lymph node size in patients with gastric cancer</article-title><source>Br J Surg</source>
<year>2003</year>
<volume>90</volume>
<fpage>1522</fpage>
<lpage>30</lpage>
</nlm-citation>
</ref>
<ref id="ref25">
<label>25</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Kim</surname>
  <given-names>JP</given-names>
</name>
<name> 
  <surname>Lee</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Kim</surname>
  <given-names>SJ</given-names>
</name>
<name> 
  <surname>Yu</surname>
  <given-names>HJ</given-names>
</name>
<name> 
  <surname>Yang</surname>
  <given-names>HK</given-names>
</name>
</person-group><article-title>Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer</article-title><source>Gastric Cancer</source>
<year>1998</year>
<volume>1</volume>
<fpage>125</fpage>
<lpage>133</lpage>
</nlm-citation>
</ref>
<ref id="ref26">
<label>26</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Yokota</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Ishiyama</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Saito</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Teshima</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Narushima</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Murata</surname>
  <given-names>K</given-names>
</name>
 <etal/>
</person-group><article-title>Lymph node metastasis as a significant prognostic factor in gastric cancer: A multiple logistic regression analysis</article-title><source>Scand J Gastroenterol</source>
<year>2004</year>
<volume>39</volume>
<fpage>380</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref27">
<label>27</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Wu</surname>
  <given-names>ZY</given-names>
</name>
<name> 
  <surname>Li</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Zhan</surname>
  <given-names>WH</given-names>
</name>
<name> 
  <surname>He</surname>
  <given-names>YL</given-names>
</name>
<name> 
  <surname>Wan</surname>
  <given-names>J</given-names>
</name>
</person-group><article-title>Effect of lymph node micrometastases on prognosis of gastric carcinoma</article-title><source>World J Gastroenterol</source>
<year>2007</year>
<volume>13</volume>
<fpage>4122</fpage>
<lpage>5</lpage>
</nlm-citation>
</ref>
<ref id="ref28">
<label>28</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Ishikawa</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Shimada</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Miyanari</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Hirota</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Takamori</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Baba</surname>
  <given-names>H</given-names>
</name>
</person-group><article-title>Pattern of lymph node involvement in proximal gastric cancer</article-title><source>World J Surg</source>
<year>2009</year>
<volume>33</volume>
<fpage>1687</fpage>
<lpage>92</lpage>
</nlm-citation>
</ref>
<ref id="ref29">
<label>29</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Saito</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Fukumoto</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Osaki</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Fukuda</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Tatebe</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Tsujitani</surname>
  <given-names>S</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic significance of level and number of lymph node metastases in patients with gastric cancer</article-title><source>Ann Surg Oncol</source>
<year>2007</year>
<volume>14</volume>
<fpage>1688</fpage>
<lpage>93</lpage>
</nlm-citation>
</ref>
<ref id="ref30">
<label>30</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Gunji</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Suzuki</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Hori</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Hayashi</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Matsubara</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Shimada</surname>
  <given-names>H</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic significance of the number of metastatic lymph nodes in early gastric cancer</article-title><source>Dig Surg</source>
<year>2003</year>
<volume>20</volume>
<fpage>148</fpage>
<lpage>53</lpage>
</nlm-citation>
</ref>
<ref id="ref31">
<label>31</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Morgagni</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Garcea</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>Marrelli</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>De Manzoni</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Natalini</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Kurihara</surname>
  <given-names>H</given-names>
</name>
 <etal/>
</person-group><article-title>Resection line involvement after gastric cancer surgery: Clinical outcome in nonsurgically retreated patients</article-title><source>World J Surg</source>
<year>2008</year>
<volume>32</volume>
<fpage>2661</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref32">
<label>32</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Sobin</surname>
  <given-names>L</given-names>
</name>
<name> 
  <surname>Wittekind</surname>
  <given-names>C</given-names>
</name>
</person-group><article-title>International Union Against Cancer: TNM Classification of Malignant Tumors.6 th ed</article-title><source>New York: Wiley;</source>
<year>2</year>
<volume></volume>
<fpage></fpage>
<comment> International Union Against Cancer: TNM Classification of Malignant Tumors 6 th ed New York: Wiley; 2002</comment>
</nlm-citation>
</ref>
<ref id="ref33">
<label>33</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Liu</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Lu</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Lu</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Xu</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Wang</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Chen</surname>
  <given-names>J</given-names>
</name>
</person-group><article-title>Clinical implications of metastatic lymph node ratio in gastric cancer</article-title><source>BMC Cancer</source>
<year>2007</year>
<volume>7</volume>
<fpage>200</fpage>
</nlm-citation>
</ref>
<ref id="ref34">
<label>34</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Marchet</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Mocellin</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Ambrosi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Morgagni</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Garcea</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>Marrelli</surname>
  <given-names>D</given-names>
</name>
 <etal/>
</person-group><article-title>The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an Italian multicentric study in 1853 patients</article-title><source>Ann Surg</source>
<year>2007</year>
<volume>245</volume>
<fpage>543</fpage>
<lpage>52</lpage>
</nlm-citation>
</ref>
<ref id="ref35">
<label>35</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Celen</surname>
  <given-names>O</given-names>
</name>
<name> 
  <surname>Yildirim</surname>
  <given-names>E</given-names>
</name>
<name> 
  <surname>Berberoglu</surname>
  <given-names>U</given-names>
</name>
</person-group><article-title>Prognostic impact of positive lymph node ratio in gastric carcinoma</article-title><source>J Surg Oncol</source>
<year>2007</year>
<volume>96</volume>
<fpage>95</fpage>
<lpage>101</lpage>
</nlm-citation>
</ref>
<ref id="ref36">
<label>36</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Yu</surname>
  <given-names>W</given-names>
</name>
<name> 
  <surname>Choi</surname>
  <given-names>GS</given-names>
</name>
<name> 
  <surname>Whang</surname>
  <given-names>I</given-names>
</name>
<name> 
  <surname>Suh</surname>
  <given-names>IS</given-names>
</name>
</person-group><article-title>Comparison of five systems for staging lymph node metastasis in gastric cancer</article-title><source>Br J Surg</source>
<year>1997</year>
<volume>84</volume>
<fpage>1305</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref37">
<label>37</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"></person-group><article-title></article-title><source></source>
<year></year>
<volume></volume>
<fpage></fpage>
</nlm-citation>
</ref>
</ref-list>

  </back>
	
</article> 




